孟鲁司特钠联合酮替芬治疗咳嗽变异性哮喘效果及对FVC、FEV1、MVV水平影响分析
|
摘要
目的分析孟鲁司特钠联合酮替芬治疗咳嗽变异性哮喘效果及对FVC、FEV1、MVV水平的影响。方法选定该院2017年6月—2018年12月收治的82例咳嗽变异性哮喘患者,随机分为对照组和研究组,各41例,对照组实施酮替芬治疗,研究组在对照组基础上联合孟鲁司特钠治疗,比较两组患者临床疗效、肺功能指标和不良反应。结果研究组患者临床治疗总有效率95.12%高于对照组70.73%(χ~2=8.613,P<0.05);研究组症状缓解时间(8.02±1.38)d、症状消失时间(11.24±2.16)d均低于对照组(t=7.361,5.965,P<0.05);治疗后研究组患者FVC (1.28±0.15)L、FEV1 (1.48±0.18)L、MVV (1.18±0.19)L/min均高于对照组(t=12.737,13.266,7.754,P<0.05);两组患者不良反应发生率差异无统计学意义(χ~2=0.213,P>0.05)。结论孟鲁司特钠与酮替芬联合可有效缓解咳嗽变异性哮喘患者咳嗽症状,改善患者肺功能,且不良反应较少,值得借鉴。
Objective To analyze the effect of montelukast sodium combined with ketotifen on cough variant asthma and its effect on FVC, FEV1 and MVV levels. Methods Eighty-two patients with cough variant asthma admitted to our hospital from June 2017 to De-cember 2018 were randomly divided into the control group and the study group, 41 cases each. The control group was treated with ketotifen. The study group was on the basis of the control group. The study group was combined with montelukast sodium to compare the clinical efficacy, lung function index and adverse reactions of the two groups. Results The total effective rate of clinical treatment was 95.12% in the study group, which was higher than 70.73% in the control group(χ~2=8.613, P <0.05). The symptom relief time(8.02±1.38) d and the disappearance time of symptoms in the study group(11.24 ±2.16) d was lower than the control group(t=7.361,5.965, P<0.05); after treatment, the patients in the study group had high FVC(1.28 ±0.15) L, FEV1(1.48±0.18) L, and MVV(1.18±0.19) L/min, higher than the control group(t=12.737, 13.266, 7.754, P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups(χ~2=0.213, P>0.05). Conclusion The combination of montelukast sodium and ketotifen can effectively alleviate the symptoms of cough in patients with cough variant asthma, improve the lung function of patients, and have few-er adverse reactions. It is worth learning.
Objective To analyze the effect of montelukast sodium combined with ketotifen on cough variant asthma and its effect on FVC, FEV1 and MVV levels. Methods Eighty-two patients with cough variant asthma admitted to our hospital from June 2017 to De-cember 2018 were randomly divided into the control group and the study group, 41 cases each. The control group was treated with ketotifen. The study group was on the basis of the control group. The study group was combined with montelukast sodium to compare the clinical efficacy, lung function index and adverse reactions of the two groups. Results The total effective rate of clinical treatment was 95.12% in the study group, which was higher than 70.73% in the control group(χ~2=8.613, P <0.05). The symptom relief time(8.02±1.38) d and the disappearance time of symptoms in the study group(11.24 ±2.16) d was lower than the control group(t=7.361,5.965, P<0.05); after treatment, the patients in the study group had high FVC(1.28 ±0.15) L, FEV1(1.48±0.18) L, and MVV(1.18±0.19) L/min, higher than the control group(t=12.737, 13.266, 7.754, P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups(χ~2=0.213, P>0.05). Conclusion The combination of montelukast sodium and ketotifen can effectively alleviate the symptoms of cough in patients with cough variant asthma, improve the lung function of patients, and have few-er adverse reactions. It is worth learning.
引文
[1]杨丽丽,顾东明,俞杰,等.富马酸酮替芬联合孟鲁司特钠治疗儿童咳嗽变异性哮喘的临床观察[J].中国药房,2016,27(32):4544-4546.
[2]张永明,林江涛.咳嗽变异性哮喘诊断和治疗新认识[J].中华结核和呼吸杂志, 2012, 35(1):62-64.
[3]宁宁,丁国标,黎海燕.酮替芬联合孟鲁司特钠治疗儿童咳嗽变异性哮喘的临床效果和安全性观察[J].中国当代医药, 2015,22(27):99-101.
[4]李彦杰.孟鲁司特钠治疗咳嗽变异性哮喘的临床分析[J].河南医学研究, 2017, 26(17):3141-3142.
[5]徐金铭.孟鲁司特钠与富马酸酮替芬联合治疗儿童咳嗽变异性哮喘的临床观察[J].泰山医学院学报, 2017, 38(7):790-792.
[6]刘雪娇.孟鲁司特钠联合酮替芬治疗咳嗽变异性哮喘的疗效分析[J].当代医学, 2016, 22(3):131-132.
[7]李倩,李立维,刘君,等.孟鲁司特钠对咳嗽变异性哮喘患者IL-4、IL-10及肺功能的影响[J].临床肺科杂志, 2016,21(8):1423-1425.
[8]陈秀锦,李丽华.孟鲁司特钠治疗咳嗽变异性哮喘患儿的近远期临床效果及对血清炎性因子的影响[J].河北医学, 2017,23(2):208-211.
[2]张永明,林江涛.咳嗽变异性哮喘诊断和治疗新认识[J].中华结核和呼吸杂志, 2012, 35(1):62-64.
[3]宁宁,丁国标,黎海燕.酮替芬联合孟鲁司特钠治疗儿童咳嗽变异性哮喘的临床效果和安全性观察[J].中国当代医药, 2015,22(27):99-101.
[4]李彦杰.孟鲁司特钠治疗咳嗽变异性哮喘的临床分析[J].河南医学研究, 2017, 26(17):3141-3142.
[5]徐金铭.孟鲁司特钠与富马酸酮替芬联合治疗儿童咳嗽变异性哮喘的临床观察[J].泰山医学院学报, 2017, 38(7):790-792.
[6]刘雪娇.孟鲁司特钠联合酮替芬治疗咳嗽变异性哮喘的疗效分析[J].当代医学, 2016, 22(3):131-132.
[7]李倩,李立维,刘君,等.孟鲁司特钠对咳嗽变异性哮喘患者IL-4、IL-10及肺功能的影响[J].临床肺科杂志, 2016,21(8):1423-1425.
[8]陈秀锦,李丽华.孟鲁司特钠治疗咳嗽变异性哮喘患儿的近远期临床效果及对血清炎性因子的影响[J].河北医学, 2017,23(2):208-211.